Aardvark Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Aardvark Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Aardvark Therapeutics, Inc. Common Stock (AARD) has a Cash Flow-to-Debt Ratio of -1.71x as of September 2025, meaning its operating cash flow of $-18.52 Million could theoretically repay -2% of its total liabilities ($10.85 Million) in one year. See AARD financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aardvark Therapeutics, Inc. Common Stock (2022–2024)
Cash flow-to-debt ratio of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. Historical debt coverage capacity for Aardvark Therapeutics, Inc. Common Stock across 3 annual periods. Also explore AARD shareholders equity momentum to track the company's year-over-year net asset growth rate.
Aardvark Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2024)
Aardvark Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2024. Year-by-year debt coverage analysis for Aardvark Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see Aardvark Therapeutics, Inc. Common Stock (AARD) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.14x | $-18.09 Million | $132.15 Million | ▼ -6.5% |
| 2023 | -0.13x | $-5.82 Million | $45.34 Million | ▲ +45.6% |
| 2022 | -0.24x | $-10.54 Million | $44.68 Million | — |